Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab

Drug Profile

Epratuzumab

Alternative Names: AMG 412; Epratucyn; hCD22; Humanised monoclonal antibody LL2; Humanized anti-CD22 monoclonal antibody IgG1; IMMU 103; IMMU LL2; LymphoCide

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Developer Charite - Universitatsmedizin Berlin; Children's Oncology Group; Immunomedics; National Cancer Institute (USA); UCB
  • Class Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen modulators; CD22 antigen modulators; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
  • Phase II Non-Hodgkin's lymphoma
  • Discontinued Cachexia

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in United Kingdom (SC, Injection)
  • 06 Dec 2016 Safety and efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 26 Feb 2016 UCB terminates its worldwide licence for epratuzumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top